2024-03-29T02:23:53Zhttp://repisalud.isciii.es/oai/requestoai:repisalud.isciii.es:20.500.12105/143852023-03-24T17:39:44Zcom_20.500.12105_2088com_20.500.12105_2052com_20.500.12105_2051col_20.500.12105_2089
Repisalud
author
Haverinen, Elsi
author
Paalanen, Laura
author
Palmieri, Luigi
author
Padron-Monedero, Alicia
author
Noguer, Isabel
author
Sarmiento Suárez, Rodrigo
author
Tolonen, Hanna
author
Joint Action on Health Information (InfAct)
funder
Unión Europea
2022-05-11T11:48:57Z
2022-05-11T11:48:57Z
2021-12-23
Arch Public Health. 2021 Dec 23;79(1):231.
0778-7367
http://hdl.handle.net/20.500.12105/14385
34949223
10.1186/s13690-021-00749-3
Archives of Public Health = Archives belges de sante publique
Background: Metabolic syndrome (MetS) is a public health problem in Europe, affecting all age groups. Several MetS definitions are available. The aim of this study was to compare four different MetS definitions in the Finnish adult population, to assess their agreement and to evaluate the impact of the choice of the definition on the prevalence of MetS. Methods: Data from FinHealth 2017, a cross-sectional national population health survey, focusing on adults aged 25 years or older were used in the analysis (n=5687). Measured data on anthropometrics, blood pressure and biomarkers together with questionnaire data were used to classify the participants into the MetS categories according to the four definitions. The definitions chosen for the comparison were those by the World Health Organization (WHO) (1998), National Cholesterol Education Program Adult Treatment Panel III (NCEP-ATP III) (2004), International Diabetes Federation (IDF) (2005), and Joint Interim Statement (JIS) (2009). Results: The four MetS definitions resulted in substantially different MetS prevalence: 17.7% by WHO, 33.3% by NCEP-ATP III, 41.5% by IDF, and 43.0% by JIS. Regardless of the definition used, the prevalence of MetS increased with age. The prevalence of the different components varied between the definitions, depending on the different cut-off points adopted. Out of all participants, only 13.6% were identified to have MetS according to all four definitions. Agreement between participants recognised by different MetS definitions, estimated through kappa coefficients, was almost perfect for IDF vs. JIS (0.97), strong for JIS vs. NCEP-ATP III (0.80), moderate for IDF vs. NCEP-ATP III (0.76) and weak for WHO vs. NCEP-ATP III (0.42), WHO vs. IDF (0.41) and WHO vs. JIS (0.40). Conclusions: Differences between observed prevalence of MetS in Finnish men and women using different MetS definitions were large. For cross-country comparisons, as well as for trend analyses within a country, it is essential to use the same MetS definition to avoid discrepancies in classification due to differences in used definitions.
eng
Diabetes
Health examination survey
Indicators
Metabolic syndrome
Population health survey
Standardization
Comparison of metabolic syndrome prevalence using four different definitions - a population-based study in Finland
journal article
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
URL
https://repisalud.isciii.es/bitstream/20.500.12105/14385/1/ComparisonMetabolicSyndromePrevalence_2021.pdf
File
MD5
4b9fd39684c4f6741da67e1450ad5e4e
553339
application/pdf
ComparisonMetabolicSyndromePrevalence_2021.pdf
URL
https://repisalud.isciii.es/bitstream/20.500.12105/14385/3/ComparisonMetabolicSyndromePrevalenceAdditionalFile1_2021.pdf
File
MD5
0a5eb12d89cb1f18c8709a9cbe11c5c7
57501
application/pdf
ComparisonMetabolicSyndromePrevalenceAdditionalFile1_2021.pdf
URL
https://repisalud.isciii.es/bitstream/20.500.12105/14385/4/ComparisonMetabolicSyndromePrevalenceAdditionalFile2_2021.pdf
File
MD5
9fa68b27e5aa3f08e3bbbf329dc85ff8
73844
application/pdf
ComparisonMetabolicSyndromePrevalenceAdditionalFile2_2021.pdf
URL
https://repisalud.isciii.es/bitstream/20.500.12105/14385/5/ComparisonMetabolicSyndromePrevalenceAdditionalFile3_2021.pdf
File
MD5
9347883e2711542b5fe1f876fb2f815f
69594
application/pdf
ComparisonMetabolicSyndromePrevalenceAdditionalFile3_2021.pdf
URL
https://repisalud.isciii.es/bitstream/20.500.12105/14385/6/ComparisonMetabolicSyndromePrevalenceAdditionalFile4_2021.pdf
File
MD5
71f32082285dbad61a5b95e2a42df4f0
66157
application/pdf
ComparisonMetabolicSyndromePrevalenceAdditionalFile4_2021.pdf
URL
https://repisalud.isciii.es/bitstream/20.500.12105/14385/7/ComparisonMetabolicSyndromePrevalenceAdditionalFile5_2021.pdf
File
MD5
d723977dbe24adad2f31102aac0f6814
66814
application/pdf
ComparisonMetabolicSyndromePrevalenceAdditionalFile5_2021.pdf
URL
https://repisalud.isciii.es/bitstream/20.500.12105/14385/9/ComparisonMetabolicSyndromePrevalence_2021.pdf.txt
File
MD5
dff077d9d58b48a5dc239b6635265dc9
46373
text/plain
ComparisonMetabolicSyndromePrevalence_2021.pdf.txt
URL
https://repisalud.isciii.es/bitstream/20.500.12105/14385/11/ComparisonMetabolicSyndromePrevalenceAdditionalFile1_2021.pdf.txt
File
MD5
82d1b121371d88ac37287bb8af905cfd
433
text/plain
ComparisonMetabolicSyndromePrevalenceAdditionalFile1_2021.pdf.txt
URL
https://repisalud.isciii.es/bitstream/20.500.12105/14385/13/ComparisonMetabolicSyndromePrevalenceAdditionalFile2_2021.pdf.txt
File
MD5
cdc494b9e0c9fed95b39e36a97b8a5ce
3344
text/plain
ComparisonMetabolicSyndromePrevalenceAdditionalFile2_2021.pdf.txt
URL
https://repisalud.isciii.es/bitstream/20.500.12105/14385/15/ComparisonMetabolicSyndromePrevalenceAdditionalFile3_2021.pdf.txt
File
MD5
fb4a55085e4daaf254e688a9c7173316
3353
text/plain
ComparisonMetabolicSyndromePrevalenceAdditionalFile3_2021.pdf.txt
URL
https://repisalud.isciii.es/bitstream/20.500.12105/14385/17/ComparisonMetabolicSyndromePrevalenceAdditionalFile4_2021.pdf.txt
File
MD5
962124a44ec53be3e9838bffaf38228a
3078
text/plain
ComparisonMetabolicSyndromePrevalenceAdditionalFile4_2021.pdf.txt
URL
https://repisalud.isciii.es/bitstream/20.500.12105/14385/19/ComparisonMetabolicSyndromePrevalenceAdditionalFile5_2021.pdf.txt
File
MD5
c1836b09f919c1693a608fab5c09918c
3047
text/plain
ComparisonMetabolicSyndromePrevalenceAdditionalFile5_2021.pdf.txt